FI4356969T3 - Fuusioituja trisyklisiä pyridatsinoniyhdisteitä, jotka ovat käyttökelpoisia ortomyksovirusinfektioiden hoidossa - Google Patents
Fuusioituja trisyklisiä pyridatsinoniyhdisteitä, jotka ovat käyttökelpoisia ortomyksovirusinfektioiden hoidossaInfo
- Publication number
- FI4356969T3 FI4356969T3 FIEP23217305.4T FI23217305T FI4356969T3 FI 4356969 T3 FI4356969 T3 FI 4356969T3 FI 23217305 T FI23217305 T FI 23217305T FI 4356969 T3 FI4356969 T3 FI 4356969T3
- Authority
- FI
- Finland
- Prior art keywords
- tai
- farmaseuttisesti
- jonkin
- sen
- compounds useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380712P | 2016-08-29 | 2016-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4356969T3 true FI4356969T3 (fi) | 2025-08-15 |
Family
ID=59923494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP23217305.4T FI4356969T3 (fi) | 2016-08-29 | 2017-08-25 | Fuusioituja trisyklisiä pyridatsinoniyhdisteitä, jotka ovat käyttökelpoisia ortomyksovirusinfektioiden hoidossa |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10160764B2 (https=) |
| EP (4) | EP3504214B1 (https=) |
| JP (3) | JP7221861B2 (https=) |
| CN (2) | CN113683614B (https=) |
| AR (1) | AR109438A1 (https=) |
| CA (1) | CA3035302A1 (https=) |
| DK (1) | DK4356969T3 (https=) |
| ES (3) | ES3042460T3 (https=) |
| FI (1) | FI4356969T3 (https=) |
| HR (1) | HRP20250885T1 (https=) |
| HU (1) | HUE072776T2 (https=) |
| JO (1) | JOP20170169A1 (https=) |
| LT (1) | LT4356969T (https=) |
| MX (1) | MX383124B (https=) |
| PL (3) | PL3848372T3 (https=) |
| PT (3) | PT3504214T (https=) |
| SI (3) | SI3848372T1 (https=) |
| TW (3) | TWI803467B (https=) |
| UY (2) | UY37378A (https=) |
| WO (1) | WO2018042303A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX377396B (es) * | 2013-09-12 | 2025-03-10 | Janssen Biopharma Inc | Compuestos de azapiridona y usos de los mismos. |
| SG11201804348SA (en) | 2015-12-15 | 2018-06-28 | Shionogi & Co | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| KR20190018469A (ko) | 2016-08-10 | 2019-02-22 | 시오노기세야쿠 가부시키가이샤 | 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물 |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| US11247993B2 (en) | 2018-01-17 | 2022-02-15 | Jiangxi Caishi Pharmaceutical Technology Co., Ltd. | Pyridone derivative, composition and use as antiviral drug thereof |
| CN118878544A (zh) * | 2018-02-28 | 2024-11-01 | 诺华股份有限公司 | 作为正粘病毒复制抑制剂用于治疗流感的化合物 |
| CN108440564B (zh) * | 2018-04-11 | 2019-08-06 | 安帝康（无锡）生物科技有限公司 | 被取代的多环氨基甲酰基吡啶酮衍生物及其前药 |
| US11312727B1 (en) | 2018-10-10 | 2022-04-26 | Janssen Biopharma, Inc. | Macrocyclic flu endonuclease inhibitors |
| CN111909174B (zh) | 2019-05-08 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物的晶型及制备方法和应用 |
| WO2021129602A1 (zh) * | 2019-12-23 | 2021-07-01 | 石家庄迪斯凯威医药科技有限公司 | 取代的多环化合物及其药物组合物和用途 |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| WO2022105669A1 (zh) * | 2020-11-17 | 2022-05-27 | 南京明德新药研发有限公司 | 含Se大环类化合物 |
| EP4707279A1 (en) * | 2023-05-02 | 2026-03-11 | Albius Sciences Beta Pte. Ltd. | Substituted tricyclic heterocyclic compound as pharmaceutical for treatment or prevention of covid-19 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2225112A (en) | 1938-07-09 | 1940-12-17 | Wright Aeronautical Corp | Air cleaner |
| GB8501542D0 (en) | 1985-01-22 | 1985-02-20 | Erba Farmitalia | 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives |
| AUPM354694A0 (en) | 1994-01-27 | 1994-02-17 | Biota Scientific Management Pty Ltd | Chemical compounds |
| ES2572030T3 (es) | 2001-08-10 | 2017-07-19 | Shionogi & Co., Ltd. | Agente antiviral |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| US20070161639A1 (en) | 2004-03-09 | 2007-07-12 | Philip Jones | Hiv integrase inhibitors |
| FR2901795A1 (fr) | 2006-05-30 | 2007-12-07 | Fourtillan Snc | Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique |
| CN102203100B (zh) | 2008-10-31 | 2014-08-27 | 盐野义制药株式会社 | 具有邻苯二酚基团的头孢菌素 |
| EP2412708A4 (en) | 2009-03-26 | 2014-07-23 | Shionogi & Co | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8927710B2 (en) | 2009-06-15 | 2015-01-06 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoylpyridone derivative |
| RU2012131124A (ru) | 2009-12-23 | 2014-01-27 | Элан Фармасьютикалз, Инк. | Птеридиноны как ингибиторы polo-подобных киназ |
| TW201201813A (en) | 2010-03-31 | 2012-01-16 | Arqule Inc | Substituted benzo-pyrido-triazolo-diazepine compounds |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| DK2620436T3 (en) | 2010-09-24 | 2018-07-30 | Shionogi & Co | Substituted polycyclic carbamoylpyridone derivative prodrug |
| US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
| RU2014113230A (ru) * | 2011-10-12 | 2015-11-20 | Шионоги Энд Ко., Лтд. | Полициклическое производное пиридона, обладающее ингибирующей активностью в отношении интегразы |
| JP6089108B2 (ja) | 2012-09-20 | 2017-03-01 | セルトリオン， インク． | ドラスタチン１０誘導体、その製造方法およびそれを含む抗癌剤組成物 |
| CA2894642A1 (en) | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| AU2014308991B2 (en) | 2013-08-21 | 2019-02-14 | Janssen Biopharma, Inc. | Antiviral compounds |
| US10098913B2 (en) | 2013-09-11 | 2018-10-16 | University Of Southern California | Composition of stem cells having highly expressed FAS ligand |
| SI3030549T1 (sl) | 2013-09-12 | 2019-08-30 | Janssen Biopharma, Inc. | Spojine piridazinona in njihove uporabe |
| MX377396B (es) | 2013-09-12 | 2025-03-10 | Janssen Biopharma Inc | Compuestos de azapiridona y usos de los mismos. |
| CN107074880A (zh) | 2014-07-07 | 2017-08-18 | 萨维拉制药有限公司 | 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途 |
| US10208045B2 (en) | 2015-03-11 | 2019-02-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| US10183945B2 (en) | 2016-03-10 | 2019-01-22 | Alios Biopharma, Inc. | Method of preparing AZA-pyridone compounds |
| RU2019102647A (ru) | 2016-07-01 | 2020-08-03 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| KR20190018469A (ko) | 2016-08-10 | 2019-02-22 | 시오노기세야쿠 가부시키가이샤 | 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물 |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| JP2019059697A (ja) * | 2017-09-28 | 2019-04-18 | 塩野義製薬株式会社 | 置換された多環性ピリダジン誘導体およびそのプロドラッグ |
| US11247993B2 (en) | 2018-01-17 | 2022-02-15 | Jiangxi Caishi Pharmaceutical Technology Co., Ltd. | Pyridone derivative, composition and use as antiviral drug thereof |
| CN110041327B (zh) | 2018-01-17 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |
| CN118878544A (zh) | 2018-02-28 | 2024-11-01 | 诺华股份有限公司 | 作为正粘病毒复制抑制剂用于治疗流感的化合物 |
| JP7282546B2 (ja) | 2018-02-28 | 2023-05-29 | 日本たばこ産業株式会社 | ４－メチルジヒドロピリミジノン化合物及びその医薬用途 |
| JP7089596B2 (ja) | 2018-02-28 | 2022-06-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体 |
| PE20210447A1 (es) | 2018-02-28 | 2021-03-08 | Japan Tobacco Inc | Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico |
-
2017
- 2017-08-24 JO JOP/2017/0169A patent/JOP20170169A1/ar unknown
- 2017-08-25 PL PL20210329.7T patent/PL3848372T3/pl unknown
- 2017-08-25 EP EP17771587.7A patent/EP3504214B1/en active Active
- 2017-08-25 PL PL23217305.4T patent/PL4356969T3/pl unknown
- 2017-08-25 ES ES23217305T patent/ES3042460T3/es active Active
- 2017-08-25 CN CN202110956692.7A patent/CN113683614B/zh active Active
- 2017-08-25 JP JP2019511749A patent/JP7221861B2/ja active Active
- 2017-08-25 ES ES20210329T patent/ES2974494T3/es active Active
- 2017-08-25 US US15/686,652 patent/US10160764B2/en active Active
- 2017-08-25 DK DK23217305.4T patent/DK4356969T3/da active
- 2017-08-25 PT PT177715877T patent/PT3504214T/pt unknown
- 2017-08-25 ES ES17771587T patent/ES2859510T3/es active Active
- 2017-08-25 SI SI201731493T patent/SI3848372T1/sl unknown
- 2017-08-25 MX MX2019002438A patent/MX383124B/es unknown
- 2017-08-25 CA CA3035302A patent/CA3035302A1/en active Pending
- 2017-08-25 LT LTEP23217305.4T patent/LT4356969T/lt unknown
- 2017-08-25 PT PT202103297T patent/PT3848372T/pt unknown
- 2017-08-25 PT PT232173054T patent/PT4356969T/pt unknown
- 2017-08-25 CN CN201780065653.XA patent/CN109863151B/zh active Active
- 2017-08-25 SI SI201731620T patent/SI4356969T1/sl unknown
- 2017-08-25 US US16/328,616 patent/US11098051B2/en active Active
- 2017-08-25 HR HRP20250885TT patent/HRP20250885T1/hr unknown
- 2017-08-25 WO PCT/IB2017/055137 patent/WO2018042303A1/en not_active Ceased
- 2017-08-25 HU HUE23217305A patent/HUE072776T2/hu unknown
- 2017-08-25 FI FIEP23217305.4T patent/FI4356969T3/fi active
- 2017-08-25 SI SI201730650T patent/SI3504214T1/sl unknown
- 2017-08-25 EP EP20210329.7A patent/EP3848372B1/en active Active
- 2017-08-25 EP EP23217305.4A patent/EP4356969B1/en active Active
- 2017-08-25 PL PL17771587T patent/PL3504214T3/pl unknown
- 2017-08-25 EP EP25187556.3A patent/EP4640279A3/en active Pending
- 2017-08-28 UY UY0001037378A patent/UY37378A/es active IP Right Grant
- 2017-08-28 UY UY0001040872A patent/UY40872A/es not_active Application Discontinuation
- 2017-08-28 TW TW106129086A patent/TWI803467B/zh active
- 2017-08-28 TW TW113134345A patent/TW202517646A/zh unknown
- 2017-08-28 TW TW112101158A patent/TWI869757B/zh active
- 2017-08-29 AR ARP170102385A patent/AR109438A1/es active IP Right Grant
-
2021
- 2021-07-13 US US17/374,237 patent/US11912715B2/en active Active
-
2022
- 2022-11-22 JP JP2022186394A patent/JP2023027102A/ja not_active Withdrawn
-
2024
- 2024-06-13 US US18/743,020 patent/US20250011334A1/en active Pending
-
2025
- 2025-01-23 JP JP2025009843A patent/JP2025081322A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4356969T3 (fi) | Fuusioituja trisyklisiä pyridatsinoniyhdisteitä, jotka ovat käyttökelpoisia ortomyksovirusinfektioiden hoidossa | |
| ES2602161T3 (es) | Copolímero aleatorio de propileno-etileno | |
| CL2013002241A1 (es) | Compuestos derivados de (4,4´-bifeniilbis(1h-imidazol-4,2-diil)-2,1-pirrolidindiil((1s)-1-((2r,6r)-2,4-dimetilltetrahidro-2h-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo, inhibidores del vhc; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso para tratar una infeccion por vhc. | |
| MX2020005543A (es) | Combinacion de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina. | |
| CA2904820C (en) | Pyridinylpyrazoloquinoline compound | |
| MX2015011778A (es) | Combinacion de farmaco. | |
| MX2017006275A (es) | Inhibidor de cinasa aurora a. | |
| MX2016001424A (es) | Composiciones edulcorantes. | |
| CU20150020A7 (es) | Composición farmacéutica recubierta que contiene regorafenib | |
| JP2014530077A5 (https=) | ||
| CL2013000677A1 (es) | Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn. | |
| MY204185A (en) | Composition and methods for the treatment of myopia | |
| de Looze et al. | BSC 2013 | |
| AR085616A1 (es) | Composicion farmaceutica inhalable que comprende glicopirrolato, uso | |
| PH12017501121A1 (en) | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors | |
| WO2017046215A3 (en) | Pharmaceutical association comprising a growth factor receptor agonist conjugated to a bioactive carrier for converting a neoplastic cell into a non-neoplastic cell and uses thereof | |
| IT201700025267A1 (it) | Gruppo per l'erogazione di agenti di lavaggio per una macchina lavatrice, in particolare una macchina lavastoviglie. | |
| CL2015002047A1 (es) | Uso de sales de tungsteno (vi) para el tratamiento de la infertilidad femenina en mamíferos no diabeticos | |
| PE20151300A1 (es) | Composicion antifungica topica para el tratamiento de onicomicosis | |
| ES2442973B1 (es) | Composición para su uso como agente antifúngico | |
| WO2019190427A3 (en) | The immediate release combination comprising raloxifene and at least one antipsychotic agent | |
| AR102810A1 (es) | Derivado de macrólido sustituido en la posición c-4 | |
| কালের কন্ঠ | ইউল্যাব ফেয়ার কাপে জয় পেল ব্র্যাক ও স্ট্যামফোর্ড ইউনিভার্সিটি | |
| MX2016002269A (es) | Tableta de duloxetina con cubierta enterica. | |
| Australia et al. | Taking stock |